Disc Medicine (NASDAQ:IRON) CEO John Quisel Sells 34,000 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 34,000 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $70.21, for a total value of $2,387,140.00. Following the completion of the sale, the chief executive officer directly owned 226,064 shares in the company, valued at $15,871,953.44. The trade was a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Disc Medicine Trading Down 0.5%

NASDAQ:IRON traded down $0.35 during mid-day trading on Tuesday, reaching $70.45. 537,249 shares of the company’s stock traded hands, compared to its average volume of 585,545. The company has a 50 day moving average price of $68.68 and a 200-day moving average price of $71.50. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -10.64 and a beta of 0.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, sell-side analysts predict that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its stake in shares of Disc Medicine by 2.2% in the fourth quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock worth $540,000 after acquiring an additional 144 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its position in shares of Disc Medicine by 3.3% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after purchasing an additional 215 shares during the last quarter. AlphaCentric Advisors LLC raised its position in shares of Disc Medicine by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock worth $254,000 after purchasing an additional 216 shares during the last quarter. Avanza Fonder AB boosted its stake in Disc Medicine by 14.1% in the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after purchasing an additional 235 shares in the last quarter. Finally, Kennedy Capital Management LLC boosted its stake in Disc Medicine by 3.3% in the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after purchasing an additional 296 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on IRON shares. Wells Fargo & Company raised their price target on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Morgan Stanley upped their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Wedbush reaffirmed an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Truist Financial cut their target price on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Disc Medicine currently has a consensus rating of “Moderate Buy” and an average target price of $105.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.